Inflammation and inducible nitric oxide synthase have no effect on monoamine oxidase activity in glioma cells

Biochemical Pharmacology

Volumn 65, Issue 10, 2003, Pages 1719-1727

  Mazzio, Elizabeth ^a   Becker, Alan ^a   Soliman, Karam F A ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Astrocyte; C6; Inflammation; Monoamine oxidase; Nitric oxide; Parkinson's disease

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; AMINE; AMINE OXIDASE (FLAVIN CONTAINING); BETA 2 ADRENERGIC RECEPTOR; CLORGYLINE; DOPAMINE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N6 (1 IMINOETHYL)LYSINE; NITRATE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; PROTEIN; SELEGILINE; TYRAMINE;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ESCHERICHIA COLI; GLIOMA CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT;

EID: 0038054418     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00148-5     Document Type: Article

References (47)

1. O'Kusky J., Colonnier M. A laminar analysis of the number of neurons, glia, and synapses in the adult cortex (area 17) of adult macaque monkeys. J. Comp. Neurol. 210:1982;278-290.
2. Squires R.F. Discovery of monoamine oxidase forms A and B. Vopr. Med. Khim. 43:1997;433-439.
3. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol. 64:2001;365-391.
4. Fowler J.S., Volkow N.D., Wang G.J., Logan J., Pappas N., Shea C., MacGregor R. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging. 18:1997;431-435.
5. Bagasra O., Michaels F.H., Zheng Y.M., Bobroski L.E., Spitsin S.V., Fu Z.F., Tawadros R., Koprowski H. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 92:1995;12041-12045.
6. Cesura A.M., Pletscher A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res. 38:1992;171-297.
7. Skorobogataia T.G. Substrate specificity of monoamine oxidase from the brain and liver of the human fetus during antenatal ontogenesis. Ukr. Biokhim. Zh. 58:1986;81-83.
8. Bredt D.S., Snyder S.H. Nitric oxide, a novel neuronal messenger. Neuron. 8:1992;3-11.
9. Bruhwyler J., Chleide E., Liegeois J.F., Carreer F. Nitric oxide: a new messenger in the brain. Neurosci. Biobehav. Rev. 17:1993;373-384.
10. Zou M.H., Daiber A., Peterson J.A., Shoun H., Ullrich V. Rapid reactions of peroxynitrite with heme-thiolate proteins as the basis for protection of prostacyclin synthase from inactivation by nitration. Arch. Biochem. Biophys. 376:2000;149-155.
11. Molina y Vedia L., McDonald B., Reep B., Brüne B., DiSilvio M., Billiar T.R., Lapetina E.G. Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. J. Biol. Chem. 267:1997;24929-24932.
12. Lizasoain I., Moro M.A., Knowles R.G., Darley-Usmar V., Moncada S. Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose. Biochem. J. 314:1996;877-880.
13. Meyerson L.R., McMurtrey K.D., Davis V.E. A rapid and sensitive potentiometric assay for monoamine oxidase using an ammonia-selective electrode. Anal. Biochem. 86:1978;287-297.
14. Bartolini B., Tipton K.F., Bianchi L., Stephenson D., Cunningham C., Della Corte L. Determination of monoamine oxidase activity by HPLC with fluorimetric detection. Neurobiology. 7:1999;109-121.
15. Pizzinat N., Copin N., Vindis C., Parini A., Cambon C. Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn Schmiedebergs Arch. Pharmacol. 359:1999;428-431.
16. Youdim M.B., Lavie L. Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci. 55:1994;2077-2082.
17. Venarucci D., Venarucci V., Vallese A., Battila L., Casado A., De la Torre R., Lopez Fernandez M.E. Free radicals: important cause of pathologies refer to ageing. Panminerva Med. 41:1999;335-339.
18. Li S.W., Lin T.S., Minteer S., Burke W.J. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Brain Res. Mol. Brain Res. 93:2001;1-7.
19. Burke W.J., Kristal B.S., Yu B.P., Li S.W., Lin T.S. Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Res. 787:1998;328-332.
20. Tabner B.J., Turnbull S., El-Agnaf O.M., Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic. Biol. Med. 32:2002;1076-1083.
21. Kristal B.S., Conway A.D., Brown A.M., Jain J.C., Ulluci P.A., Li S.W., Burke W.J. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 30:2001;924-931.
22. Naoi M., Maruyama W., Takahashi T., Akao Y., Nakagawa Y. Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. J. Neural Transm. Suppl. 58:2000;111-121.
23. Law A., Gauthier S., Quirion R. Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity. Br. J. Pharmacol. 133:2001;1114-1124.
24. Feinstein D.L. Suppression of astroglial nitric oxide synthase expression by norepinephrine results from decreased NOS-2 promoter activity. J. Neurochem. 70:1998;1484-1496.
25. 2A receptor activation inhibits inducible nitric oxide synthase activity in C6 glioma cells. Life Sci. 61:1997;1819-1827.
26. Holt A., Sharman D.F., Baker G.B., Palcic M.M. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal. Biochem. 244:1997;384-392.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
28. Park S.K., Murphy S. Duration of expression of inducible nitric oxide synthase in glial cells. J. Neurosci. Res. 39:1994;405-411.
29. Evans S.M., Casartelli A., Herreros E., Minnick D.T., Day C., George E., Westmoreland C. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicol. In Vitro. 15:2001;579-584.
30. Chandler L.J., Kopnisky K., Richards E., Crews F.T., Sumners C. Angiotensin II decreases inducible nitric oxide synthase expression in rat astroglial cultures. Am. J. Physiol. 268:1995;C700-C707.
31. Mazzio E., Becker A., Soliman K.F.A. Characterization of neurotransmitters and dopamine on attenuation of inducible nitric oxide synthase in glioma cells. J. Neuroimmunol. 131:2002;70-82.
32. Feinstein D.L., Galea E., Roberts S., Berquist H., Wang H., Reis D.J. Induction of nitric oxide synthase in rat C6 glioma cells. J. Neurochem. 62:1994;315-321.
33. Cawthon R.M., Breakefield X.O. Differences in the structures of monoamine oxidases A and B in rat clonal cell lines. Biochem. Pharmacol. 32:1983;441-448.
34. Oreland L., Gottfries C.G. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog. Neuropsychopharmacol. Biol. Psychiatry. 10:1986;533-540.
35. Hotamisligil G.S., Girmen A.S., Fink J.S., Tivol E., Shalish C., Trofatter J., Baenziger J., Diamond S., Markham C., Sullivan J. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov. Disord. 9:1994;305-310.
36. Fratiglioni L., Wang H.X. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav. Brain Res. 113:2000;117-120.
37. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R.R., Schlyer D.J., Zezulkova I., Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proc. Natl. Acad. Sci. U.S.A. 93:1996;14065-14069.
38. Kotake Y., Tasaki Y., Makino Y., Ohta S., Hirobe M. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J. Neurochem. 65:1995;2633-2638.
39. Thomas T., McLendon C., Thomas G. L-Deprenyl: nitric oxide production and dilation of cerebral blood vessels. Neuroreport. 9:1998;2595-2600.
40. Boomershine C.S., Lafuse W.P., Zwilling B.S. β2-Adrenergic receptor stimulation inhibits nitric oxide generation by Mycobacterium avium infected macrophages. J. Neuroimmunol. 101:1999;68-75.
41. Porter J.T., McCarthy K.D. Astrocytic neurotransmitter receptors in situ and in vivo. Prog. Neurobiol. 51:1997;439-455.
42. Chang J.Y., Liu L.Z. Catecholamines inhibit microglial nitric oxide production. Brain Res. Bull. 52:2000;525-530.
43. Pahan K., Namboodiri A.M., Sheikh F.G., Smith B.T., Singh I. Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J. Biol. Chem. 272:1997;7786-7791.
44. Kuiper M.A., Visser J.J., Bergmans P.L., Scheltens P., Wolters E.C. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. J. Neurol. Sci. 121:1994;46-49.
45. Rauhala P., Mohanakumar K.P., Sziraki I., Lin A.M., Chiueh C.C. S-Nitrosothiols and nitric oxide, but not sodium nitroprusside, protect nigrostriatal dopamine neurons against iron-induced oxidative stress in vivo. Synapse. 23:1996;58-60.
46. Dobrucki L.W., Kalinowski L., Uracz W., Malinski T. The protective role of nitric oxide in the brain ischemia. J. Physiol. Pharmacol. 51:2000;695-703.
47. Mason R.B., Pluta R.M., Walbridge S., Wink D.A., Oldfield E.H., Boock R.J. Production of reactive oxygen species after reperfusion in vitro and in vivo: protective effect of nitric oxide. J. Neurosurg. 93:2000;99-107.